Pathogenesis and treatment strategies of novel coronavirus pneumonia: Reflections on immune checkpoint inhibitor-related adverse events in lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 LIU Baodong

Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, P.R.China;

Corresponding author：

LIU Baodong, Email: xwliubaodong@aliyun.com

Keywords：

Coronavirus disease 2019 (COVID-19); lung cancer; immune checkpoint inhibitors; immune-related adverse events

DOI：

10.7507/1007-4848.202002032

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In December 2019, an outbreak of pneumonia associated with the coronavirus disease 2019 (COVID-19) occurred in Wuhan, China. The lung imaging finding is like that of the lung cancer immune checkpoint inhibitors (ICI) associated pneumonia. Therefore, we speculated that they may have similar pathogenesis and treatment strategies, which is reviewed in this article in order to provide some reference to timely and effectively reduce the fatality rate of COVID-19.

Citation： LIU Baodong. Pathogenesis and treatment strategies of novel coronavirus pneumonia: Reflections on immune checkpoint inhibitor-related adverse events in lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(5): 597-599. doi: 10.7507/1007-4848.202002032 Copy

1.	Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology, 2020, 295(1): 16-17.
2.	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol, 2017, 35(7): 709-717.
3.	Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol, 2016, 27(7): 1362.
4.	Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. J Thorac Oncol, 2018, 13(12): 1930-1939.
5.	Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest, 2017, 152(2): 271-281.
6.	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus ocetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
7.	Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci, 2017, 108(5): 1000-1006.
8.	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373(17): 1627-1639.
9.	Lisberg A, Cummings A, Goldman JW, et al. A phase Ⅱ study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol, 2018, 13(8): 1138-1145.
10.	Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol, 2018, 4(8): 1112-1115.
11.	Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017, 50(2): 1700050.
12.	Wu C, Zheng S, ChenY, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. MedRxiv, 2020. [Epub ahead of print].
13.	Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020. [Epub ahead of print].
14.	Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review. JAMA, 2019, 322(8): 764-774.
15.	Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small cell lung cancer treated with pembrolizumab: Results from the phase Ⅰ KEYNOTE-001 study. J Clin Oncol, 2019, 37(28): 2518-2527.
16.	Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med, 2019, 381(21): 2020-2031.
17.	Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature, 2016, 537(7620): 417-421.
18.	Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol, 2018, 36(28): 2872-2878.
19.	Ricciuti B, Dahlberg SE, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol, 2019, 37(22): 1927-1934.
20.	Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 2020. [Epub ahead of print].
21.	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10222): 391-393.
22.	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020. [Epub ahead of print].

1. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology, 2020, 295(1): 16-17.
2. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol, 2017, 35(7): 709-717.
3. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol, 2016, 27(7): 1362.
4. Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. J Thorac Oncol, 2018, 13(12): 1930-1939.
5. Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest, 2017, 152(2): 271-281.
6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus ocetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
7. Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci, 2017, 108(5): 1000-1006.
8. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373(17): 1627-1639.
9. Lisberg A, Cummings A, Goldman JW, et al. A phase Ⅱ study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol, 2018, 13(8): 1138-1145.
10. Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol, 2018, 4(8): 1112-1115.
11. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017, 50(2): 1700050.
12. Wu C, Zheng S, ChenY, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. MedRxiv, 2020. [Epub ahead of print].
13. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020. [Epub ahead of print].
14. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review. JAMA, 2019, 322(8): 764-774.
15. Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small cell lung cancer treated with pembrolizumab: Results from the phase Ⅰ KEYNOTE-001 study. J Clin Oncol, 2019, 37(28): 2518-2527.
16. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med, 2019, 381(21): 2020-2031.
17. Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature, 2016, 537(7620): 417-421.
18. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol, 2018, 36(28): 2872-2878.
19. Ricciuti B, Dahlberg SE, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol, 2019, 37(22): 1927-1934.
20. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 2020. [Epub ahead of print].
21. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10222): 391-393.
22. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020. [Epub ahead of print].

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Pathogenesis and treatment strategies of novel coronavirus pneumonia: Reflections on immune checkpoint inhibitor-related adverse events in lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content